

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND (3) CHANGES OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, Mr. Yan Jia (“**Mr. Yan**”) has been appointed as an independent non-executive Director, with effect from December 26, 2025. The biographical details of Mr. Yan are set out as follows:

Mr. Yan Jia, aged 54, served as a lawyer at Paul Weiss Rifkind Wharton & Garrison LLP from September 1999 to April 2001, a chief operating officer at iSinoLaw Limited from May 2001 to March 2006, a lawyer at Paul Hastings LLP from April 2006 to October 2008 and a partner at Paul Hastings LLP from November 2008 to May 2024. He has served as a partner and Co-Chair of China Practice at Pillsbury Winthrop Shaw Pittman LLP since May 2024; an independent director of Aba Chemicals Corporation since March 2022 (a company listed on the Shenzhen Stock Exchange; stock code: 300261); an independent director of InventisBio Co., Ltd. since December 2020 (a company listed on the Shanghai Stock Exchange; stock code: 688382); and an independent director of Shanghai Feilo Acoustics Co., Ltd. since May 2021 (a company listed on the Shanghai Stock Exchange; stock code: 600651).

Mr. Yan obtained a bachelor’s degree in law and master’s degree in law from Fudan University in July 1993 and July 1996, respectively. He obtained a master’s degree in law from Yale University in June 1999 and a doctorate degree in international financial law from City University of Hong Kong in November 2003. Mr. Yan was admitted to the New York State bar in December 2000 and is a registered foreign lawyer with the Law Society of Hong Kong. He also obtained the legal professional qualification certificate issued by the Ministry of Justice of the PRC in 1994.

Mr. Yan has obtained legal advice pursuant to Rule 3.09D of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and has confirmed that he understood his obligations as a director of the Company. The Company has received written confirmation of independence according to Rule 3.13 of the Listing Rules from Mr. Yan. The nomination committee of the Company had assessed and reviewed the independence of Mr. Yan with reference to the independence criteria as set out in Rule 3.13 of the Listing Rules. The Board is also not aware of any circumstance that might influence Mr. Yan in exercising independent judgment, and is satisfied that he has the required character, integrity, independence and experience to fulfil the role of an independent non-executive Director and he will be able to maintain an independent view of the Group’s affairs. The Board considers him to be independent. The Board is of the view that Mr. Yan will provide professional advice on corporate governance, legal and compliance risk prevention, bringing diversity and professionalism to the Board.

Pursuant to the appointment letter entered into between Mr. Yan and the Company on December 26, 2025, Mr. Yan was appointed for a specific term of three years from December 26, 2025. The appointment letter is determinable without payment of compensation (other than statutory compensation) by the Company serving immediate written notice to Mr. Yan, or Mr. Yan serving not less than three months’ written notice to the Company. Mr. Yan is entitled to an annual director’s fee of RMB360,000.00 which is determined by the Board with reference to his duties and responsibilities with the Company and the current market situation and subject to review from time to time.

Mr. Yan is also subject to retirement and re-election at the next following annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once every three years according to the articles of association of the Company and the Listing Rules.

As at the date hereof, save as disclosed herein, Mr. Yan (i) does not have any relationship with any Directors, senior management, substantial or controlling shareholder(s) (as defined in the Listing Rules) of the Company; (ii) does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other positions with the Company and/or other members of the Group; and (iv) has not held any other directorship in the last three years in other public companies the securities of which are listed on any securities market in Hong Kong or overseas.

There is no information which is discloseable nor is Mr. Yan involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matter concerning Mr. Yan that needs to be brought to the attention of the shareholders of the Company.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the appointment of Mr. Yan as an independent non-executive Director, he has also been appointed as a member of the audit committee and a member of the environmental, social and governance committee of the Company, with effect from December 26, 2025.

RESIGNATION OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

The Board hereby announces that, with effect from December 26, 2025, due to personal work arrangement, Ms. Wong Yuen Ki (“**Ms. Wong**”) has tendered her resignation as a joint company secretary of the Company and ceased to be an authorized representative of the Company (the “**Authorized Representative**”) under Rule 3.05 of the Listing Rules and the process agent of the Company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”).

Ms. Wong confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and/or the shareholders of the Company.

APPOINTMENT OF JOINT COMPANY SECRETARY

Following the resignation of Ms. Wong, the Board announces that Mr. Lee Leong Yin (“**Mr. Lee**”) has been appointed as the joint company secretary of the Company with effect from December 26, 2025.

The biographical details of Mr. Lee are set out below:

Mr. Lee is a senior manager of company secretarial services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. Mr. Lee has over 15 years of experience in the company secretarial field. Mr. Lee has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Mr. Lee is a Chartered Secretary, a Chartered Governance Professional and a fellow of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

Mr. Lee possesses the academic or professional qualifications of a company secretary as required under Rule 3.28 of the Listing Rules.

With effect from December 26, 2025, the joint company secretaries of the Company are Ms. Zhong Shengli and Mr. Lee.

APPOINTMENT OF AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

Following the resignation of Ms. Wong, she has also ceased to be an Authorized Representative and the Process Agent with effect from December 26, 2025. The Board announces that Mr. Lee, the newly appointed joint company secretary of the Company, has been appointed as an Authorized Representative and the Process Agent with effect from December 26, 2025. With effect from December 26, 2025, the Authorized Representatives and Process Agents are Ms. Sun Yuan and Mr. Lee.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 28, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.